Alectinib (ALECENSA) is THE ONLY preferred first-line treatment option (Category 1) for ALK+ metastatic NSCLC in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) 4*
*When an ALK rearrangement is discovered prior to first-line systemic therapy.
1L PFS Results
View PFS results vs crizotinib from the head-to-head ALEX
CNS Efficacy in 1L ALK+ mNSCLC
Learn more about CNS efficacy with ALECENSA.
1L Safety Profile
Learn about the 1L safety profile with ALECENSA.